PIASKY

This brand name is authorized in Lithuania, United States

Active ingredients

The drug PIASKY contains one active pharmaceutical ingredient (API):

1 Crovalimab UNII H9KH1GP3UU - CROVALIMAB

Crovalimab is a recombinant humanised immunoglobulin G1 (IgG1)-based monoclonal antibody that specifically binds with high affinity to component 5 (C5) of the complement system, inhibiting its cleavage into C5a and C5b and thus preventing the formation of the membrane attack complex (MAC). Crovalimab causes terminal complement activity inhibition. In patients with PNH, crovalimab inhibits terminal complement-mediated intravascular haemolysis. Read about Crovalimab

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
PIASKY Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR
PIASKY Solution for injection/infusion	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AJ07		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1100819
Country: US	FDA, National Drug Code	Identifier(s): 50242-115